Alkermes plc.
Alkermes plc is a biopharmaceutical company focused on neuroscience, with commercial medicines for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy. Its business combines proprietary branded products with manufacturing and royalty revenue from partnered products developed under license. The company is headquartered in Ireland, with a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio. In 2026 it expanded its commercial portfolio by acquiring Avadel Pharmaceuticals and adding LUMRYZ, a narcolepsy treatment, to its marketed products.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueBranded medicines that Alkermes markets and sells itself, including treatments for schizophrenia, bipolar I disorder, alcohol dependence, opioid dependence and narcolepsy.
Revenue from producing products for licensees and other partners, including legacy and partnered medicines manufactured at Alkermes facilities or through contractors.
Royalties earned on sales of licensed products that incorporate Alkermes technology, where partners commercialize the medicine and pay usage-based royalties.
Products
Reported · share of revenue- Vivitrol31.7 %
- Aristada and Aristada Initio25.1 %
- LYBALVI23.5 %
- Royalty16.6 %
- Manufacturing Revenue3.1 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Alkermes sells primarily into the U.S. pharmaceutical channel, where wholesalers, specialty distributors and pharmacies purchase its proprietary products. The end users are physicians and treatment systems serving patients with serious psychiatric and substance-use disorders, so demand is driven by prescribing behavior, reimbursement access and treatment adherence. For partnered products, the direct customers are licensees and sublicensees that commercialize products using Alkermes technology and pay manufacturing or royalty fees. The company also serves public treatment systems and private practice physicians through its sales and education efforts, reflecting a mix of commercial and healthcare-system buyers.
Wholesalers, specialty distributors and pharmacies purchase proprietary products for resale and dispensing, making this the core commercial route for ARISTADA, LYBALVI, VIVITROL and LUMRYZ.
Psychiatrists, addiction-treatment providers and public health systems prescribe or administer Alkermes medicines because they address chronic neuropsychiatric and substance-use conditions.
Biopharma partners that commercialize products incorporating Alkermes technology buy manufacturing capacity or generate royalty streams for the company.
Insurers, Medicaid and Medicare Part D programs influence uptake through rebates, formulary access and reimbursement terms, especially for VIVITROL and other branded therapies.
Strategy
Alkermes is focused on growing a neuroscience portfolio built around differentiated commercial products and selective business development. Near term, the company is emphasizing execution on ARISTADA, ARISTADA INITIO, LYBALVI, VIVITROL and newly acquired LUMRYZ, while continuing to support manufacturing and royalty streams from partnered products. It also seeks to expand through transactions, licenses and collaborations that add products, candidates or technologies with commercial fit. This strategy matters because the company depends on a relatively concentrated set of branded medicines, so adding durable assets and protecting supply/manufacturing reliability are central to sustaining growth.
Most revenue comes from a concentrated set of branded medicines, so uptake, access and retention are critical to growth.
The company wants to reduce concentration risk and add assets that fit its neuroscience commercial infrastructure.
Product shortages or quality issues could directly reduce sales and damage reputation in regulated pharmaceutical markets.
Geography
2025Alkermes is headquartered in Ireland but operates a U.S.-centric commercial model, with its marketed products sold primarily in the United States. The company also has a corporate office and R&D center in Massachusetts and a manufacturing facility in Wilmington, Ohio, which anchors production of several proprietary products and microspheres for partnered medicines. Some manufacturing and royalty revenue is earned outside the U.S., and the company notes exposure to foreign-currency movements on those revenues and related expenses. Operationally, the geography mix matters because U.S. commercial execution drives most revenue, while Ireland is relevant for tax and corporate structure and Ohio is critical for supply continuity.
Share of the revenue the company reports by geography.
Risks
Alkermes is exposed to concentration risk because a large share of revenue comes from a small number of proprietary products, so any loss of exclusivity, slower uptake or reimbursement pressure could materially affect results. Manufacturing risk is also significant because the company relies on complex pharmaceutical production, third-party contractors and regulated supply chains; quality deviations, shortages or site disruptions could delay shipments or trigger recalls. Competition is intense in neuroscience and addiction treatment, including from branded and generic rivals as well as products from licensees that may compete with Alkermes medicines. The company also faces foreign-currency exposure on non-U.S. manufacturing and royalty revenue, plus legal and IP risk around products such as INVEGA TRINZA and other licensed assets.
- Concentration in key proprietary productsImpact: HighLikelihood: Medium
The company says substantial revenue comes from its key proprietary products, so any decline in demand or access can have an outsized effect on earnings.
Exposure - Manufacturing and supply-chain disruptionImpact: HighLikelihood: Medium
Pharmaceutical manufacturing is complex and disruptions in API, quality, equipment, labor or logistics can cause shortages, recalls or lost sales.
Exposure - Competition in neuroscience and addiction marketsImpact: MediumLikelihood: Medium
Competing branded therapies, generics and alternative treatments can pressure pricing, market share and physician adoption.
Exposure - Controlled-substance regulatory burdenImpact: MediumLikelihood: Medium
LUMRYZ and sodium oxybate are subject to DEA quotas and heightened controls, which can constrain manufacturing and distribution.
Exposure: Narcolepsy franchise
- Foreign-currency exposureImpact: LowLikelihood: Medium
Some manufacturing and royalty revenues are earned outside the U.S. and denominated in local currencies, creating translation and transaction risk.
Exposure: Non-U.S. royalty and manufacturing revenue
Accounting
Judgemental itemsDifferent revenue streams are recognized at different times, so product sales, manufacturing revenue and royalties are not directly comparable across periods.
Impact: Can shift reported revenue between quarters depending on shipment timing and licensee sales
Some manufacturing revenue depends on end-market sales data from licensees, requiring estimates that are later reconciled.
Impact: Creates short-term volatility and potential adjustments within the same quarter
Net product sales are reduced by contractual adjustments that depend on utilization and payer mix, especially for VIVITROL.
Impact: Can materially affect reported net sales and margins
LUMRYZ manufacturing and distribution are tightly regulated, increasing the importance of inventory planning, compliance and potential write-downs if supply is disrupted.
Impact: May affect cost of goods sold and inventory valuation
Similar listed companies
Publicly listed companies with a comparable business focus.
Avadel Pharmaceuticals PLC
Pharmaceutical Preparations
Avadel Pharmaceuticals plc is a U.S.-based biopharmaceutical company focused on sleep-disorder therapies, with LUMRYZ as its only commercial product.
Oculis Holding AG
OCS · Pharmaceutical Preparations
Oculis Holding AG is a Switzerland-based biopharmaceutical company focused on therapies for neuro-ophthalmology and ophthalmology.
Neurocrine Biosciences, Inc
NBIX · Biological Products, (No Diagnostic Substances)
Neurocrine Biosciences is a U.S.-based biopharmaceutical company focused on neuroscience and related endocrine disorders.
Vanda Pharmaceuticals Inc.
VNDA · Pharmaceutical Preparations
Alnylam Pharmaceuticals, Inc
ALNY · Pharmaceutical Preparations
BioCryst Pharmaceuticals, Inc
BCRX · Biological Products, (No Diagnostic Substances)
Biocryst Pharmaceuticals is a U.S.-based biotechnology company focused on rare diseases, with its core commercial product ORLADEYO for hereditary angioedema (HAE).
Last updated: 24/09/2026